CEL-SCI Corp

NYSE American:CVMUnited States

CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system. The Company is focused on the development of product candidates and technologies, such as Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers, and Ligand Epitope Antigen Presentation System (LEAPS), with several product candidates under development for the potential treatment of rheumatoid arthritis. Multikine is a biological medicinal immunotherapy comprising a mixture of natural cytokines and small biological molecules. Multikine is injected around the tumor and adjacent lymph nodes for three weeks as a first-line treatment before the standard of care (SOC), which is surgery followed by either radiotherapy or chemoradiotherapy. Multikines rationale for use is to incite a locoregional immune response against the tumor.

Contact Information

Headquarters

SUITE 802, 8229 BOONE BLVD .VIENNA, VA, United States 22182

Phone

703-506-9460

Fax

703-506-9471

Executives

Independent Chairman of the Board

Robert Watson

Chief Executive Officer, Chief Financial Officer, Treasurer, Director

Geert Kersten

Senior Vice President - Operations, Corporate Secretary

Patricia Prichep

Senior Vice President - Regulatory Affairs

John Cipriano

Senior Vice President - Research, Cellular Immunology

Daniel Zimmerman